Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL27682289 | 0.86 | HTR6 (0.47) | HTR6LMNASMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL13257975 | 0.86 | KDM4E (0.51) | HTR6CA1CA2LMNA | |
| SCHEMBL29651100 | 0.85 | HTR6 (0.64) | HTR6AKR1C3AKR1C1CA12CA9 | |
| SCHEMBL1996382 | 0.85 | HTR6 (0.64) | HTR6AKR1C3AKR1C1CA12CA9 | |
| SCHEMBL1015250 | 0.83 | HTR6 (0.58) | HTR6AKR1C3AKR1C1CA12CA9 | |
| SCHEMBL19737423 | 0.83 | HTR6 (0.59) | HTR6AKR1C3AKR1C1CA12CA9 | |
| SCHEMBL12496662 | 0.83 | ACLY (0.56) | HTR6LMNASMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL947296 | 0.82 | HTR6 (0.60) | HTR6LMNASMN1; SMN2 | |
| SCHEMBL950569 | 0.81 | HTR6 (0.61) | HTR6 | |
| SCHEMBL19737553 | 0.81 | HTR6 (0.49) | HTR6AKR1C3AKR1C1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605168-B2 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| CN-101048407-A | Bicyclic heteroaryl PDE4B inhibitors | PLEXXIKON INC (US) | 2007-10-03 | — | — | CN | disclosed |
| EP-1786813-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | HTR6 2439/4885AKR1C3 3503/4885AKR1C1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.